FOR IMMEDIATE RELEASE
January 12, 2022
Contact: Katie Edmiston | Marketing Manager
NCODA WELCOMES NEW EXECUTIVE COUNCIL MEMBERS
CAZENOVIA, NY – NCODA today announced the appointment of four new members to the Executive Council. With the growth of NCODA, the Executive Council has been instrumental in facilitating a strong path forward for patient-centered and collaborative oncology care.
“With leadership representatives from across the nation, the Executive Council will continue to help support NCODA’s Mission and commitment to providing better care to cancer patients. We are pleased to welcome these new Executive Council members,” said Randy Erickson, RN, BSN, MBA, CEO of Utah Cancer Specialists and Chair of the NCODA Executive Council. “They join at an exciting time as we continue to drive positive change in oncology care; always focused on our patients.”
“I am personally delighted to welcome such a strong group of new Executive Council members, and I look forward to serving with each of them in the coming year,” said Jim Schwartz, RPh, NCODA President. “The dedication from this group of leaders will bring diverse expertise and insight to the next chapter of NCODA.”
The new Executive Council members are:
- Sam Abdelghany, PharmD, MHA, BCOP, Executive Director of Oncology Pharmacy Services, Smilow Cancer Hospital at Yale New Haven
Prior to Sam’s current role, he was the Coordinator of the Investigational Drug Service, where he supported Yale investigators conducting NIH, pharmaceutical, or Yale-sponsored clinical studies. Sam has a Master of Health Care Administration degree from Ohio University and serves on various committees including the Yale University Institutional Review Board as the Chair of the Oncology Board.
- Neal Dave, PharmD | Executive Director of Pharmacy | Texas Oncology
Neal oversees both the oral and IV medications across all Texas Oncology locations, is currently on the US Oncology P&T Executive Committee and has been a member since 2018. Neal earned his PharmD degree from the University of Texas.
- Stuart Genschaw, MHA, MBA | Chief Operating Officer | Cancer & Hematology Centers of Western Michigan
Stuart leads a practice with numerous locations across West Michigan, is an active consultant and advisor to physician practices, and received his MHA from Western Michigan University with an MBA from the University of Colorado.
- Luis Raez, MD, FACP, FCCP | Medical Director and Chief Scientific Officer | Memorial Cancer Institute
Luis is the immediate past President of the Florida Society of Clinical Oncology (FLASCO) and is Co-Director of the MCI/FAU Florida Cancer Center designated by the Florida governor. Prior to joining Memorial Cancer Institute, Luis was an associate professor of Medicine, Epidemiology and Public Health, and Co-director of Thoracic Oncology at Sylvester Cancer Center.
NCODA Founder and Executive Director, Michael Reff, RPh, MBA said, “The field of oncology has shown continuous innovation and development of numerous anti-cancer therapies. Therefore, the need for a collaborative, consistent approach to cancer care is vital to ensuring the best possible outcomes for patients. I feel very privileged to be part of this group of leaders. The Executive Council knows that it’s imperative to bring positive change and advocacy, and so we work tirelessly each day for our patients!”
NCODA, Inc. is a 501(c)(3) organization. Our Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. For more information about NCODA’s Executive Council and general updates, visit www.ncoda.org.